Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
Business Wire•18/09/2026•09:00 ET
0
Get started
Create a free account to read the full story and Whiz Insights.